Casdatifan is another HIF-2 inhibitor that’s been tested in a large phase I study, a study of monotherapy dose escalation with an extended cohort at the MTD but also in combination with other drugs such as cabozantinib, which we presented before. In this presentation during GU ’26 we focussed on the totality of the data for monotherapy. It was a very large study for a phase I therapy and we saw activities across dosage.

Interestingly enough, also this builds on the strong translational arm of this phase I where we show a significant decrease in serum EPO. Think about it as a pharmacodynamic – more increase is better response rate. We also looked at EPO mRNA and other biomarkers, we looked at toxicity and there was nothing besides the anaemia, hypoxia known that are side effects of HIF=2 inhibitors.

Finally, what this is important to present is folks to be familiar with this drug because this drug is going into phase III trials. Actually we do have a phase III trial in combination with cabozantinib versus cabozantinib only in metastatic patients after immunotherapy, a study by the name PEAK-1. So hopefully the totality of the data will lead to embarking on accrual with PEAK-1 and finishing this study.

I think it’s good to have another HIF-2 inhibitor around, it’s good to have a choice and it’s good for patients.